Addex' ADX10059 Has Potential For Parkinson's Disease Levodopa Induced Dyskinesia (PD-LID)

Allosteric modulation company Addex Pharmaceuticals (SWISS: ADXN) reported that its lead product, ADX10059, which is nearing completion of Phase IIb testing in gastroesophageal reflux disease (GERD) and migraine prevention, also has demonstrated significant potential in a non-human primate model of Parkinson's disease levodopa induced dyskinesia (PD-LID).